Clinical trials: Thrombopenia
Chemotherapy-Induced Thrombocytopenia
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Hetrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of solid tumors.
- Trial name
- NCT03976882
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Immune Thrombocytopenic Purpura
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP
- Trial name
- NCT02077192
- Testing
- Fostamatinib Disodium
- Where
- 55 sites in United States, Australia and 13 more
- Volunteers
- 123 people
- Sponsor
- Rigel Pharmaceuticals
Autoimmune Thrombocytopenia, Warm Autoimmune Haemolytic Anaemia
IASO-782 in Autoimmune Hematological Diseases
This study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with autoimmune hematological diseases.
- Trial name
- NCT06534021
- Testing
- IASO-782 injection
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Shanghai IASO Biotechnology Co., Ltd
Primary Myelofibrosis, Post-Polycythemia Vera
A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis
This study assessed the safety and efficacy of Panobinostat as a single agent in the treatment of Primary Myelofibrosis, Post-Polycythemia Vera and Post-Essential Thrombocythemia.
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocytopenia
- Trial name
- NCT00931762
- Testing
- Panobinostat
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Immune Thrombocytopenia
Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months
This study will evaluate the safety and efficacy of avatrombopag in subjects with a confirmed diagnosis of primary ITP (≤6 months duration) over 26 weeks of treatment, and also evaluate the incidence of ITP remission.
- Trial name
- NCT05046327
- Testing
- Avatrombopag 20 mg Oral Tablet
- Sponsor
- Sobi, Inc.
Immune Thrombocytopenia
A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)
The main purpose of this study is to assess the efficacy and safety of LIV-GAMMA SN Inj. in adult subjects with ITP. The primary objective of this study is to determine the responder rate.
- Trial name
- NCT03164915
- Testing
- LIV-GAMMA SN Inj.
- Where
- 6 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- SK Plasma Co., Ltd.
Immune Thrombocytopenia (ITP), ITP
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
- Conditions
- Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal
- Trial name
- NCT07043946
- Testing
- Budoprutug
- Where
- 20 sites in Bulgaria, Greece and 3 more
- Volunteers
- 24 people
- Sponsor
- Climb Bio, Inc.
Thrombocytopenia, Hematologic Malignancy
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
This prospective, multicenter, randomized, open-label, Phase 2, parallel, dose ranging, multidose trial will enroll patients into 3 Thrombosomes dose groups and 1 control liquid stored platelets (LSP) group in order to evaluate…
- Conditions
- Thrombocytopenia, Hematologic Malignancy, Bone Marrow Aplasia, Myeloproliferative Disorders
- Trial name
- NCT04631211
- Testing
- Thrombosomes, Liquid Stored Platelets (LSP)
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 21 people
- Sponsor
- Cellphire Therapeutics, Inc.
Idiopathic Thrombocytopenic Purpura (ITP)
Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
The primary purpose of this study is to evaluate the safety of multiple doses of Staphylococcal protein A (PRTX-100) in adult patients with Idiopathic Thrombocytopenia Purpura (ITP).
- Trial name
- NCT00571467
- Testing
- PRTX-100 (Staphylococcal protein A)
- Where
- 7 sites in Australia, New Zealand
- Volunteers
- 9 people
- Sponsor
- Protalex, Inc.
Chronic Primary Immune Thrombocytopenia (ITP)
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients with Chronic Primary Immune Thrombocytopenia
- Trial name
- NCT06004856
- Testing
- Orelabrutinib
- Where
- 45 sites in China
- Volunteers
- 195 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Immune Thrombocytopenic Purpura
Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim
Chronic immune thrombocytopenic purpura (ITP) is characterized by low platelet counts and the risk of severe bleeding complications.
- Trial name
- NCT01439321
- Testing
- Eltrombopag, Romiplostim
- Volunteers
- 280 people
- Sponsor
- GlaxoSmithKline